

Hepatitis B Vaccine

©2013 Truven Health Analytics Inc. Proprietary and confidential.

MEASURE DESCRIPTION:

Hepatitis B Vaccine indicates whether a child, who turned 2 years old during the measurement year, received three (3) hepatitis B vaccinations. This excludes children who had a previous adverse reaction to a vaccine, as well as those with a vaccine contraindication such as immunodeficiency syndrome, HIV, lymphoreticular or histiocytic tissue cancer, multiple myeloma, or leukemia.

This measure is based on the HEDIS measure *Childhood Immunization Status* (CIS).

PROPRIETARY STATUS:

This measure is owned by NCQA [NQF-Endorsed TM].

CRITERIA REVISION:

-This measure is based on the HEDIS ® 2013 Technical Specifications for Physician Measurement criteria.

CRITERIA REVIEW DATE: 04/01/2013

MEASURE TYPE: Quality - process of care

MEASURE PACKAGE: Advantage Nationally Endorsed

MINIMUM DATA REQUIREMENTS (months): 24

MEASURE DETAILS:

DENOMINATOR:

Identifies the unique count children who turned 2 years old during the measurement year. This excludes children who had a previous adverse reaction to a vaccine, as well as those with a vaccine contraindication such as immunodeficiency syndrome, HIV, lymphoreticular or histiocytic tissue cancer, multiple myeloma, or leukemia.

Age in years (as of the end of the measurement year)	Age in Years = 2
--	------------------

EXCLUSIONS:

Excludes from the eligible population all children who had a previous adverse reaction to a vaccine, as well as those with a vaccine contraindication such as immunodeficiency syndrome, HIV, lymphoreticular or histiocytic tissue cancer, multiple myeloma, or leukemia. Children who have a contraindication for one vaccine are excluded from the denominator for all vaccine rates and combination rates, since the denominator for all rates must be the same. Contraindications are checked as far back as possible in the patient's history, but must have occurred by their 2nd birthday.

Anaphylactic reaction to the vaccine or its components (anytime prior to the child's 2nd birthday)	ICD-9 Diagnosis Code = 999.4, 999.42
OR	
Encephalopathy (anytime prior to the child's 2nd birthday)	ICD-9 Diagnosis Code = 323.51 And ICD-9 Diagnosis Code = E948.4, E948.5, E948.6

OR	
Immunodeficiency syndromes, HIV disease, asymptomatic HIV, cancer of lymphoreticular or histiocytic tissue, multiple myeloma, or leukemia (anytime prior to the child's 2nd birthday)	ICD-9 Diagnosis Code = 042, 200.00-208.91, 279*, V08

NUMERATOR:

Identifies children, who turned 2 years old during the measurement year, and received three (3) hepatitis B vaccinations with different dates of service on or before the child's 2nd birthday. Evidence of the antigen or vaccine, a documented history of the illness, or a seropositive test result are counted in the numerator.

3 hepatitis B vaccinations received on different dates of service (anytime prior to the child's 2nd birthday), or a history of the disease	CPT Procedure Code = 90723, 90740, 90744, 90747, 90748
	Or
	HCPCS Procedure Code = G0010
	Or
	ICD-9 Diagnosis Code = 070.2*, 070.3*, V02.61

CONTINUOUS ENROLLMENT:

Continuously enrolled with medical coverage for the 12 months prior to the child's 2nd birthday, which equates to 12 months out of 12 months.

MEASURE BACKGROUND:

The national vaccine immunization program is a very successful preventive care program in the United States. An example is the greater-than-99 percent decrease in cases of invasive *Haemophilus influenzae* type B (HiB) infection since the introduction of a specific immunization in 1987. Vaccine-preventable diseases were a major cause of morbidity and mortality in children before the institution of routine immunizations. Rubella caused devastating congenital defects in children born to infected mothers. Hepatitis B, infecting approximately 250,000 in the U.S., may lead to liver failure or malignancy. Varicella infection (chicken pox) is generally mild, but results in school and work absences, and fatalities rarely occur.

Prevention of disease is essential for both patient health and control of medical costs. Immunization against hepatitis A and B, diphtheria, tetanus, pertussis, HiB, polio, rotavirus, measles, mumps, rubella, varicella zoster virus (VZV), pneumococcus, influenza, meningococcus, and human papillomavirus is considered the standard for the United States. The use of combination vaccines helps reduce the number of inoculations at each visit and improve compliance. Most of the immunizations are given as combined vaccines during routine well-child checks in the first 2 years of life.

In 2009, only 69.9 percent of U.S. toddlers 19 to 35 months of age had received their basic immunization series (≥ 4 doses of DTP/DTaP, ≥ 3 doses of poliovirus vaccine, ≥ 1 dose of measles-containing vaccine, ≥ 3 doses of HiB vaccine, ≥ 3 doses of hepatitis B vaccine, and ≥ 1 dose of varicella vaccine). Even with generally good coverage by school age, there may be many delays in the vaccination schedule. When current scheduling guidelines aren't followed, children remain susceptible to these preventable diseases, particularly when cases of the illness can be imported from other countries. Benefits and risks are associated with using all immunizations. Patient benefits include partial or complete protection against infection. Societal benefits include prevention of disease outbreaks, and reduction in healthcare-related costs.

Vaccination risks range from common, minor, and local adverse effects to rare, severe, and life-threatening conditions. Therefore, recommendations for vaccination practices balance scientific evidence of benefits for each person and to society against the potential costs and risks for vaccination for the individual and programs.

These Measures are intended to assist physicians in enhancing quality of care. Measures are designed for use by any physician who manages the care of a patient for a specific condition or for prevention. These performance Measures are not clinical guidelines and do not establish a standard of medical care. The Consortium has not tested its measures for all potential applications. The Consortium encourages the testing and evaluation of its Measures.

Measures are subject to review and may be revised or rescinded at any time by the Consortium. The Measures may not be altered without the prior written approval of the Consortium. Measures developed by the Consortium, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial uses of the Measures require a license agreement between the user and American Medical Association, on behalf of the Consortium. Neither the Consortium nor its members shall be responsible for any use of these Measures.

The Measures are provided as is without warranty of any kind. ©2007 American Medical Association. All Rights Reserved.

CPT® copyright 2012 American Medical Association. All rights reserved. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Applicable FARS/DFARS restrictions apply to government use. CPT is a registered trademark of the American Medical Association.

The LOINC® codes, LOINC® table (regardless of format), LOINC® Release Notes, LOINC® Changes File, and LOINC® Users Guide are copyright© 1995-2012, Regenstrief Institute, Inc., and the Logical Observation Identifiers Names and Codes (LOINC) Committee. All rights reserved.

NCQA Notice of Use. Broad public use and dissemination of these measures is encouraged and the measure developers have agreed with NQF that noncommercial uses do not require the consent of the measure developer. Use by health care providers in connection with their own practices is not commercial use. Commercial use of a measure does require the prior written consent of the measure developer. As used herein, a • commercial use• refers to any sale, license, or distribution of a measure for commercial gain, or incorporation of a measure into any product or service that is sold, licensed, or distributed for commercial gain (even if there is no actual charge for inclusion of the measure).

These performance measures were developed and are owned by the National Committee for Quality Assurance (• NCQA•). These performance measures are not clinical guidelines and do not establish a standard of medical care. NCQA makes no representations, warranties, or endorsement about the quality of any organization or physician that uses or reports performance measures and NCQA has no liability to anyone who relies on such measures. NCQA holds a copyright in this measure and can rescind or alter this measure at any time. Users of the measure shall not have the right to alter, enhance, or otherwise modify the measure and shall not disassemble, recompile, or reverse engineer the source code or object code relating to the measure. Anyone desiring to use or reproduce the measure without modification for a noncommercial purpose may do so without obtaining any approval from NCQA. All commercial uses must be approved by NCQA and are subject to a license at the discretion of NCQA.

© 2009-2012 National Committee for Quality Assurance. All rights reserved.

RED BOOK™ is a trademark of Truven Health Analytics Inc.
